Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2026Cancer Research

MaaT013 Fecal Microbiotherapy Enhances Gut Health and Delays GvHD Symptoms

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJulie ReygnerMSMargaux De SeilhacCGCyrielle Gasc

Discussion

Loading...

Member takes

Overview

Proof-of-concept study shows MaaT013 improves gastrointestinal function and reduces GvHD in humanized mice, indicating therapeutic potential.

Key Points

  • The study aims to investigate how MaaT013 fecal microbiotherapy can influence graft-versus-host disease through gut microbiota restoration and immune modulation.
  • Utilized in vitro models to assess leaky gut and inflammation effects.
  • Conducted in vivo studies with humanized mouse models to observe GvHD symptoms.
  • Applied transcriptomic analysis to understand gene expression changes in colon tissue.
  • Combined metagenomics and metabolomics to analyze microbiota and metabolites in the gut.
  • MaaT013-derived metabolites were shown to control inflammation in an in vitro leaky gut model.
  • MaaT013 modulated immune responses by activating TLR and NOD sensors, increasing IL-10 production and enhancing Treg cells.
  • Beneficial bacteria from MaaT013 effectively engrafted in germ-free mice, producing anti-inflammatory metabolites.
  • MaaT013 delayed the onset of GvHD symptoms in humanized mouse models.

Cite This Study

Reygner et al. (2026) studied this question.

synapsesocial.com/papers/69d1fc8ea79560c99a0a231dhttps://doi.org/10.1158/1538-7445.am2026-2868
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MaaT013 fecal microbiotherapy modulates key gastro-intestinal and immunological processes involved in GvHD pathogenesis in vitro and in vivo2026
  2. 2Abstract 6687: Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT034) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors2024
  3. 3Multi-omics analysis of a fecal microbiota transplantation trial identifies novel aspects of acute graft-versus-host disease pathogenesis2024 · 14 citations
  4. 4Control of gvhd by probiotics with a single strain of muribaculaceae bacterium through secretory proteins2025 · 1 citations
  5. 5Data from Multi-omics Analysis of a Fecal Microbiota Transplantation Trial Identifies Novel Aspects of Acute GVHD Pathogenesis2024